Patent Number: 8,877,202

Title: Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Abstract: Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.

Inventors: Govindan; Serengulam V. (Summit, NJ), McBride; William J. (Boonton, NJ), Sathyanarayan; Nalini (Edison, NJ), Mazza-Ferreira; Christine (Park Ridge, NJ), Goldenberg; David M. (Mendham, NJ)

Assignee: Immunomedics, Inc.

International Classification: A61K 39/00 (20060101); A61K 39/395 (20060101)

Expiration Date: 2019-11-04 0:00:00